Loading...
Please wait, while we are loading the content...
Similar Documents
Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
| Content Provider | Europe PMC |
|---|---|
| Author | Song, Guoqi Ni, Huiyun Zou, Linqing Wang, Shukui Tian, Fuliang Liu, Hong Cho, William C |
| Copyright Year | 2016 |
| Abstract | ObjectivesThe objective of this study was to investigate the expression level of CD40 and its role in the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with rituximab-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).Design and methodsThe immunohistochemical expressions of CD40 in 186 well-characterized DLBCL patients were evaluated by tissue microarrays, thereby revealing the relationship of the molecule CD40 with known tumor, patient-related variables, and survival rates.ResultsThe results showed that CD40 expressions were not statistically different between the germinal center B-cell-like (GCB) type and the non-GCB type. We also analyzed the relationships of CD40 expression with overall survival (OS) and progression-free survival (PFS) in DLBCL patients who were uniformly treated with R-CHOP. A low expression of CD40 compared to high expression is related to poor OS and PFS.ConclusionOur findings indicate that the CD40 level at onset acts as an independent prognostic predictor of DLBCL patients treated with R-CHOP. |
| Journal | Oncotargets and Therapy |
| Volume Number | 9 |
| PubMed Central reference number | PMC4922817 |
| PubMed reference number | 27382316 |
| e-ISSN | 11786930 |
| DOI | 10.2147/ott.s96992 |
| Language | English |
| Publisher | Dove Medical Press |
| Publisher Date | 2016-06-23 |
| Access Restriction | Open |
| Rights License | The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. © 2016 Song et al. This work is published and licensed by Dove Medical Press Limited |
| Subject Keyword | CD40 diffuse large B-cell lymphoma R-CHOP prognostic factor |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Oncology |
